Such factors include, among others: (i) the risk that the Company does not execute its business plan, because of insufficient financing, inefficacy of products or other reasons; (ii) the inability of the Company to keep pace with technological advancements in the field of genetic diagnostics and the treatment of tropical parasitic diseases; (iii) the Company's inability to adequately protect its intellectual property or the Company's inadvertent infringement of third party intellectual property; (iv) the Company not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for the Company's products not developing as expected; (vii) the Company's inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; (ix) the risk that the Company's drugs may not be approved for sale by regulators having authority over medicine and drug therapies; and (x) the potential inability to effectively market and commercialize the Company's technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

Investor and Media contact:

Samantha Haynes
1-800-539-0289 or
info@upstreambio.com


Source: Upstream Biosciences Inc. (OTCBB: OPBS) http://www.upstreambio.com
Maximum News Dissemination by Filing Services Canada Inc.
Ph: (403) 717-3898  Fx: (403) 717-3896    www.usetdas.com